Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

Direct Aromatic 18F-labeling of Tetrazines: A Rapid and Convenient Entry to Tetrazines for Pretargeted PET Imaging

Rocio Garcia Vazquez, Umberto Maria Battisti, Daniel Lloyd Stares, Ida Nymann Petersen, Francois Crestey, Dennis Svatunek, Hannes Mikula, Jesper L. Kristensen, Andreas Kjaer and Matthias Herth
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 134;
Rocio Garcia Vazquez
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umberto Maria Battisti
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Lloyd Stares
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ida Nymann Petersen
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
2Cluster for Molecular Imaging, Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Crestey
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Svatunek
3Vienna University of Technology (TU Wien) Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannes Mikula
3Vienna University of Technology (TU Wien) Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper L. Kristensen
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Kjaer
4Department of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet Copenhagen Denmark
2Cluster for Molecular Imaging, Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Herth
4Department of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet Copenhagen Denmark
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

134

Introduction: Recently, tetrazines have been successfully developed as pretargeted imaging agents. Particularly, they have been of interest when used with trans-cyclooctene (TCO) modified mAbs for pretargeted immunoimaging due to their fast reaction kinetics in vivo as well as their high specificity. (1) Pretargeting is based on a two-step process in which a TCO-tagged nanomedicine, for example an antibody, is administered and allowed to accumulate followed by a short-lived radiolabeled tetrazine. The latter reagent is able to form a stable covalent conjugate with the TCO through a bioorthogonal reaction. (2,3) This approach results in an enhanced safety profile as well as a higher image quality when compared to conventional radioimmunoimaging. (4) Many attempts to label highly reactive tetrazines with 18F, the most ideal nuclide for PET imaging, have been attempted. However, no successful 18F-direct labeling approach has been reported so far with enough radiochemical yields (RCYs). (5) In this work, we successfully developed a direct aromatic 18F-labeling approach of tetrazines.

Methods: Initially, a low reactive methyl-tetrazine was selected as a model compound to evaluate the feasibility of the synthesis and radiolabelling of a set of precursors through direct aromatic fluorinations (Figure 1). Thereafter, the best labeling approach was optimized in respect to labeling conditions varying temperature, time and base amount. In a next step, we studied the substrate scope of the reaction on a set of tetrazines including methyl-, H-, phenyl- and pyridyl- tetrazines (Figure 2). The effect of electron withdrawing and electron donating groups on the aromatic ring was evaluated in terms of synthetic accessibility, radiochemical conversion (RCC) and RCY (Figure 3).

Results: Out of all tested labeling reactions, radiolabeling only succeeded through Cu-mediated 18F-fluorination using stannate precursors (Figure 1). Moderate to good RCYs (10-24%) were obtained for methyl-, phenyl- and H-tetrazines. 2-Pyridyl structures were prohibitive, most likely due to a chelation effect of copper with the respective pyridyl moieties of the tetrazines (Figure 2). Subsequently, we investigated which substitution pattern of the H-tetrazine yielded in highest RCYs. Best results were obtained with a 3,5-substitution pattern (Figure 3).

Conclusions: This work showed the first 18F-direct labeling strategy of highly reactive tetrazines, starting from organotin precursors via a Cu-mediated approach. The developed procedure is simple, short, reproducible as well as scalable and as such, superior to previously used 18F-multistep labeling strategies with regard to clinical applications. Currently, we are working on the first directly 18F-radiolabeled tetrazine structures, which will be used for pretargeted brain and cancer imaging. Acknowledgments: This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 813528. This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 668532: Click-it.Figure 1. Radiolabeling strategies using different methyl-tetrazine precursors to probe the fluorination.Figure 2. Radiolabeling with Cu-mediated fluorination reaction of higher reactive tetrazines. *The radiolabeled compound was never isolated. †Preliminary studies based on n=2.Figure 3. Study of the RCCs when including in the aromatic ring different linkers. *The stannate precursor was never isolated. **The radiolabeled compound was never isolated. †Preliminary studies based on n=2.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Direct Aromatic 18F-labeling of Tetrazines: A Rapid and Convenient Entry to Tetrazines for Pretargeted PET Imaging
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Direct Aromatic 18F-labeling of Tetrazines: A Rapid and Convenient Entry to Tetrazines for Pretargeted PET Imaging
Rocio Garcia Vazquez, Umberto Maria Battisti, Daniel Lloyd Stares, Ida Nymann Petersen, Francois Crestey, Dennis Svatunek, Hannes Mikula, Jesper L. Kristensen, Andreas Kjaer, Matthias Herth
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 134;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Direct Aromatic 18F-labeling of Tetrazines: A Rapid and Convenient Entry to Tetrazines for Pretargeted PET Imaging
Rocio Garcia Vazquez, Umberto Maria Battisti, Daniel Lloyd Stares, Ida Nymann Petersen, Francois Crestey, Dennis Svatunek, Hannes Mikula, Jesper L. Kristensen, Andreas Kjaer, Matthias Herth
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 134;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • Evaluation of Methods to Decrease Formation of a Higher Molecular Weight Species When211At-Labeling of Antibody-B10 Conjugates Using Chloramine-T as Oxidant
  • Predictive modeling of tau aggregation and propagation using PET and DTI
  • Design of calcium-sensing receptor targeted thera(g)nostic agents
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Radiopharmaceutical Sciences (RPSC) YIA Symposium

  • 18F-FDG PET/CT of extramedullary disease in newly diagnosed multiple myeloma: imaging findings and its correlation with clinical indicators and outcome
  • Delta-like Ligand 3 (DLL3) is a novel target for molecular imaging of Neuroendocrine Prostate Cancer
  • Copper(I)-mediated 11C-carboxylation of (hetero)arylstannanes: radiosynthesis of [11C]bexarotene.
Show more Radiopharmaceutical Sciences (RPSC) YIA Symposium

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire